To Get Full Access :

NCE-1 Intelligence & Market Opportunity

Orlynvah

Sulopenem Etzadroxil And Probenecid
Antibiotic
Oral Tablets

Orlynvah is an oral tablet for adult women with uncomplicated urinary tract infections caused by E. coli, K. pneumoniae, or P. mirabilis, especially for those with limited or no alternative oral antibiotic options. It combines sulopenem (an antibiotic) with probenecid, which helps increase sulopenem levels, delivering strong antibacterial activity comparable or superior to ciprofloxacin and amoxicillin/clavulanate in clinical trials.

Approval Date
25-Oct-24
NCE-1 Date
25-Oct-28
NCE Date
25-Oct-29
Commercial snapshot

Market performance & projections

Revenue ($M)
NA
CAGR (%)
NA
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
NA
2027
NA
2028
NA
2029
NA
2030
NA
2031
NA
2032
NA
Molecule profile

Details & specifications

Molecule
Sulopenem Etzadroxil And Probenecid
Innovator
ITERUM THERAPEUTICS US LTD
Dosage Form
Oral Tablets
Strength
500 mg; 500 mg
Therapeutic Category
Antibiotic
Usage
To treat uncomplicated urinary tract infections (uUTI)
Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data
Milestones tracked against primary FDA sources and refreshed continuously.
Analyst-built projections
Seven-year sales outlooks modeled by our pharma intelligence team.
First-to-file focus
Exclusivity windows framed around the decisions generics teams actually make.
Partnership on demand
From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?